SCHEDULE: Two Seas Capital Discloses 9.4% Stake in Arbutus Biopharma

Two Seas Capital LP and Sina Toussi have reported a 9.4% beneficial ownership stake in Arbutus Biopharma Corporation.

Summary

• Two Seas Capital LP, its general partner, and Sina Toussi have filed a Schedule 13G reporting beneficial ownership of 18,557,543 common shares of Arbutus Biopharma Corporation.
• This holding represents 9.4% of the company's total outstanding common shares as of March 31, 2026.
• The shares are held across two investment funds: Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP.
• The reporting persons maintain sole voting and dispositive power over the entire 18,557,543 share position.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest and long-term commitment from a specialized investment firm.

Positives

• Institutional investor confidence is demonstrated by a significant 9.4% equity position.
• The investment is held by specialized funds, suggesting a strategic interest in the company's LNP (Lipid Nanoparticle) technology platform.

Negatives

• The filing indicates a passive investment stance, which may limit the influence of the shareholder on corporate strategy.

Risks

• The investment is subject to the general market risks associated with the biotechnology sector.
• The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing control, which may limit their ability to advocate for major corporate changes.

Future Outlook

The filing does not provide a forward-looking outlook for the company, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

StockSavvy.ai notes that institutional accumulation of Arbutus Biopharma shares often correlates with market interest in the company's proprietary LNP delivery technology, which is a critical component in modern genetic medicine development.

Comparison to Industry Standards

• The 9.4% stake is a significant position for an investment firm, aligning with typical institutional 'block' holdings in mid-cap biotech firms.
• The filing follows standard regulatory requirements for institutional investors exceeding the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a validation of the company's long-term value proposition.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Keywords

Arbutus Biopharma, Two Seas Capital, Schedule 13G, Institutional Ownership, Biotechnology, LNP Technology